GlaxoSmithKline to Disclose More Study Data to Qualified Scientists

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlaxoSmithKline Plc (GSK) plans to disclose more individual patient data from its clinical trials to increase transparency in how it reports drug-study results. Since May, qualified researchers can request access to findings on individual patients whose identities are concealed and confidentiality protected. The drugmaker will double the number of studies to 400 available by year’s end to researchers seeking data of approved medicines and of therapies that have been terminated from development, Perry Nisen, senior vice president of science and innovation at Glaxo, said in a report published yesterday in the New England Journal of Medicine.

Help employers find you! Check out all the jobs and post your resume.

Back to news